相似文献
1
A meta-analysis of the success rate of Helicobacter pylori therapy in Canada.
Can J Gastroenterol. 2007 May;21(5):295-300. doi: 10.1155/2007/419784.
2
3
Optimum duration of regimens for Helicobacter pylori eradication.
Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2.
4
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Am J Gastroenterol. 2010 Jan;105(1):65-73. doi: 10.1038/ajg.2009.508. Epub 2009 Sep 15.
5
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.
6
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006. Epub 2016 Apr 19.
7
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Am J Gastroenterol. 2017 Sep;112(9):1374-1381. doi: 10.1038/ajg.2017.195. Epub 2017 Jul 18.
8
High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.
9
Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Helicobacter. 2005 Jun;10(3):157-71. doi: 10.1111/j.1523-5378.2005.00307.x.
10
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11.
引用本文的文献
1
Success of Guideline-based Treatment of Newly Diagnosed and Previously Treated Patients During 2007-2021 in Edmonton, Alberta.
J Can Assoc Gastroenterol. 2023 Dec 14;7(3):221-229. doi: 10.1093/jcag/gwad051. eCollection 2024 Jun.
2
The Effect of Helicobacter pylori Eradication on Gastric Wall Thickness in Patients Undergoing Laparoscopic Sleeve Gastrectomy.
Obes Surg. 2021 Sep;31(9):4024-4032. doi: 10.1007/s11695-021-05513-8. Epub 2021 Jun 1.
3
Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Can J Gastroenterol Hepatol. 2016;2016:7321574. doi: 10.1155/2016/7321574. Epub 2016 Mar 29.
4
With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?
Can J Gastroenterol Hepatol. 2014 Sep;28(8):417-8. doi: 10.1155/2014/140864.
5
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?
World J Gastroenterol. 2013 Dec 7;19(45):8168-80. doi: 10.3748/wjg.v19.i45.8168.
6
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.
Can J Gastroenterol. 2013 Dec;27(12):701-6. doi: 10.1155/2013/143047.
7
Optimum duration of regimens for Helicobacter pylori eradication.
Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2.
8
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
World J Gastroenterol. 2012 Aug 28;18(32):4386-90. doi: 10.3748/wjg.v18.i32.4386.
9
Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.
Can J Gastroenterol. 2010 May;24(5):303-6. doi: 10.1155/2010/637908.
10
Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection.
J Gastroenterol. 2008;43(6):429-33. doi: 10.1007/s00535-008-2187-4. Epub 2008 Jul 4.
本文引用的文献
1
Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD002096. doi: 10.1002/14651858.CD002096.pub4.
2
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Am J Gastroenterol. 2006 Mar;101(3):488-96. doi: 10.1111/j.1572-0241.2006.00637.x.
3
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Am J Gastroenterol. 2006 Feb;101(2):243-7. doi: 10.1111/j.1572-0241.2006.00457.x.
4
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
Aliment Pharmacol Ther. 2006 Feb 15;23(4):481-8. doi: 10.1111/j.1365-2036.2006.02793.x.
5
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Aliment Pharmacol Ther. 2004 Nov 15;20(10):1071-82. doi: 10.1111/j.1365-2036.2004.02248.x.
6
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.
Clin Gastroenterol Hepatol. 2004 Nov;2(11):997-1002. doi: 10.1016/s1542-3565(04)00458-6.
7
Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection.
Can J Gastroenterol. 2004 Sep;18(9):547-54. doi: 10.1155/2004/326767.
8
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Can J Gastroenterol. 2003 Sep;17(9):533-8. doi: 10.1155/2003/425293.
9
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Am J Gastroenterol. 2003 Sep;98(9):1963-9. doi: 10.1111/j.1572-0241.2003.07583.x.
10
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Aliment Pharmacol Ther. 2003 Sep 15;18(6):647-54. doi: 10.1046/j.1365-2036.2003.01746.x.
Zotero 插件